SS&H Financial Advisors Inc. Has $2.81 Million Stock Holdings in Pfizer Inc. $PFE

SS&H Financial Advisors Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 33.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,943 shares of the biopharmaceutical company’s stock after buying an additional 28,043 shares during the period. SS&H Financial Advisors Inc.’s holdings in Pfizer were worth $2,812,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Stratos Wealth Advisors LLC boosted its holdings in Pfizer by 7.3% in the fourth quarter. Stratos Wealth Advisors LLC now owns 71,621 shares of the biopharmaceutical company’s stock worth $1,783,000 after acquiring an additional 4,872 shares in the last quarter. Perpetual Ltd increased its holdings in shares of Pfizer by 16.8% during the fourth quarter. Perpetual Ltd now owns 130,052 shares of the biopharmaceutical company’s stock valued at $3,238,000 after acquiring an additional 18,660 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors raised its position in shares of Pfizer by 150.5% during the fourth quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 29,929 shares of the biopharmaceutical company’s stock worth $745,000 after purchasing an additional 17,983 shares during the period. Cromwell Holdings LLC lifted its holdings in shares of Pfizer by 25.4% in the 4th quarter. Cromwell Holdings LLC now owns 18,472 shares of the biopharmaceutical company’s stock worth $460,000 after purchasing an additional 3,740 shares in the last quarter. Finally, Relyea Zuckerberg Hanson LLC lifted its holdings in shares of Pfizer by 20.8% in the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 15,110 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 2,598 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on PFE shares. HSBC boosted their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Royal Bank Of Canada began coverage on shares of Pfizer in a report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price on the stock. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Stock Performance

NYSE PFE opened at $28.37 on Friday. The company has a fifty day moving average price of $27.09 and a 200-day moving average price of $25.82. The firm has a market cap of $161.29 billion, a price-to-earnings ratio of 20.86 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the firm earned $0.63 earnings per share. The firm’s revenue was down 1.2% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.